Drug Profile

Loncastuximab tesirine - ADC Therapeutics

Alternative Names: ADCT-402; Anti-CD19-PBD-conjugate-ADC; Lonca; Lonca-T; loncastuximab tesirine-lpyl; MT-2111; ZYNLONTA

Latest Information Update: 28 Aug 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ADC Therapeutics; Spirogen
Developer ADC Therapeutics; Mitsubishi Tanabe Pharma Corporation; Swedish Orphan Biovitrum
Class Antineoplastics; Benzodiazepines; Drug conjugates; Immunotoxins; Monoclonal antibodies; Pyrroles
Mechanism of Action Alkylating agents; DNA cross linking agents

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Mantle-cell lymphoma; Diffuse large B cell lymphoma
New Molecular Entity Yes

Marketed Diffuse large B cell lymphoma
Preregistration B-cell lymphoma
Phase II Follicular lymphoma; Marginal zone B-cell lymphoma; Waldenstrom's macroglobulinaemia
Phase I/II Mantle-cell lymphoma
Phase I Non-Hodgkin's lymphoma
Discontinued Precursor B-cell lymphoblastic leukaemia-lymphoma

12 Aug 2025 ADC Therapeutics announces intention to submit supplemental BLA to US FDA for Diffuse large B-cell lymphoma (Combination therapy, Second-line therapy or greater) in the first half of 2026
12 Aug 2025 Efficacy and adverse event data from a phase II LOTIS-7 trial in relapsed or refractory Diffuse large B-cell lymphoma was presented at the European Hematology Association 2025 Congress (EHA-2025) and the 18th International Conference on Malignant Lymphoma (ICML-2025) released by ADC Therapeutics
12 Aug 2025 Updated efficacy and adverse event data from a phase II trial in Marginal zone B-cell lymphoma presented at the 18th International Conference on Malignant Lymphoma (ICML-2025) released by ADC Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com